CHOP / CEOP 항암화학요법 프로토콜

동물 종별 용량

용량은 면허 수의 전문가를 위한 임상 참고 자료입니다. 항상 최신 라벨과 개별 환자에 대해 확인하십시오.

투여 경로

금기

• Severe myelosuppression (neutrophil count < 3 x 10^9/l)
• Pre-existing severe cardiac dysfunction (relative contraindication for doxorubicin; use mitoxantrone instead)
• Active haemorrhagic cystitis (substitute cyclophosphamide with chlorambucil)
• MDR1 mutation (requires significant dose reduction or avoidance of vincristine and doxorubicin)

이상반응

• Myelosuppression (neutropenia, thrombocytopenia)
• Gastrointestinal toxicity (vomiting, diarrhea, anorexia)
• Haemorrhagic cystitis (specific to cyclophosphamide)
• Severe tissue necrosis if extravasated (vincristine, doxorubicin)
• Cardiotoxicity (specific to doxorubicin)
• Alopecia (breed dependent)

약물 상호작용

• Cimetidine · Alters hepatic cytochrome P450 enzyme pathway, potentially altering the metabolism and increasing toxicity of chemotherapeutics. · major

모니터링

• Haematology prior to each treatment
• Nadir neutrophil count 7 days after the first doxorubicin treatment
• Free-catch urine dipstick prior to each cyclophosphamide administration (check for blood)
• Urine culture if blood is noted on dipstick
• Biochemistry prior to first treatment and minimum every 6 months
• Baseline echocardiography (especially before doxorubicin if pre-existing heart disease is suspected)

과용량

Overdosage of any component of the CHOP protocol can lead to **life-threatening myelosuppression** (profound neutropenia and sepsis), severe gastrointestinal mucosal sloughing, and acute cardiotoxicity (doxorubicin). Treatment is strictly supportive, including broad-spectrum IV antibiotics, aggressive fluid therapy, anti-emetics, and potentially granulocyte colony-stimulating factor (G-CSF).